The “Development of Biomaterial-based Delivery Systems for Parkinson’s illness – an Integrated Pan-European Approach” plan (short: BrainMatTrain) has perceived 4 M€ from a EU’s Horizon 2020 extend programme, underneath a Marie Skłodowska-Curie European Training Networks Action.
The BrainMatTrain-project will rise new record to aim both a inflammatory and neurodegenerative phases of Parkinson’s disease, as currently, a symptoms of a illness are treated regulating drugs that do not residence a underlying means of a disease, or delayed down on-going neuro-degeneration.
The consortium hopes to rise a initial disease-modifying therapy for Parkinson’s that could delayed down a course of a illness rather than charity small symptomatic benefits. The idea of a plan is to operative functionalised biomaterials that will satisfy neuroregeneration in a Parkinsonian brain. These biomaterials will supply a internal microenvironment around shop-worn hankie with suitable healing signalling factors.
Professor Jenny Emnéus from DTU Nanotech participates in a consortium that consists of partners from France, Austria, Sweden, a Netherlands, a United Kingdom and Ireland from both universities and industry. The plan is headed by Centre for Research in Medical Devices during NUI Galway, Ireland.
The plan will run for 4 years from 2016-2020.